Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Advances With Checkpoint Inhibitors, T-Cell Engagers, and ADCs Converge to Reshape the SCLC Treatment Paradigm

November 16th 2025

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

Dr Marron on the Evolving Role of Tarlatamab in SCLC

November 15th 2025

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Dr Bhora on How Perioperative Immunotherapy Is Reshaping the Treatment Paradigm in Resectable NSCLC

November 15th 2025

Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.

Phase 3 Data Illuminate Advancing Roles for T-DXd and Combination Approaches in HER2+ Breast Cancer

November 14th 2025

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

B7-H3–Targeted ADC HN-20093 Shows Strong Efficacy, Is Still Safe at Higher Dose in R/R Sarcomas

November 14th 2025

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

Dr Jakubowiak on How the PERSEUS Study Informed the ATLAS Trial in Multiple Myeloma

November 13th 2025

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

Dr Randall on the Need for Precision Survivorship Care in Pediatric and AYA Sarcoma

November 13th 2025

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

November 13th 2025

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

November 13th 2025

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer

November 13th 2025

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Ifinatamab Deruxtecan Development Continues in Phase 3 Study After Robust Results in Pretreated ES-SCLC

November 12th 2025

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.

Dr Raab on the Rationale for Adding Teclistamab to Daratumumab-Based Induction in NDMM

November 12th 2025

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Dr Saeed on the Rationale for Evaluating the Combination of Zanzalintinib Plus Atezolizumab vs Regorafenib in mCRC

November 11th 2025

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

FDA Approves OncoMate MSI Dx as Companion Diagnostic for Pembrolizumab/Lenvatinib in MSS Endometrial Cancer

November 11th 2025

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS

November 11th 2025

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma

November 11th 2025

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

Oncology Experts Debate the Potential for AI to Improve Timely Access to Care

November 11th 2025

Incorporating AI into daily workflows may allow oncology professionals to save time on insurance denial claims and re-allocate time back into patient care.

Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC

November 10th 2025

Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10th 2025

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.